The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Ophthalmology, Guiyang, China.
Zhongshan Hospital of Traditional Chinese Medicine, Ophthalmology, Zhongshan, China.
Front Endocrinol (Lausanne). 2024 Apr 22;15:1320632. doi: 10.3389/fendo.2024.1320632. eCollection 2024.
A systematic evaluation and Meta-analysis were performed to determine the relationship between IL-17A levels in ocular aqueous and peripheral venous serum samples and diabetic retinopathy (DR).
PubMed, Embase, Web of Science, and CNKI databases were searched from the time of library construction to 2023-09-20.The results were combined using a random-effects model, sensitivity analyses were performed to determine whether the arithmetic was stable and reliable, and subgroup analyses were used to look for possible sources of heterogeneity.
A total of 7 case-control studies were included. The level of IL-17A was higher in the Nonproliferative DR(NPDR) group than in the Non-DR(NDR) group [SMD=2.07,95%CI(0.45,3.68),P=0.01], and the level of IL-17A in the proliferating DR(PDR) group was higher than that of the NDR group [SMD=4.66,95%CI(1.23,8.08),P<0.00001]. IL-17A levels in peripheral serum and atrial fluid were significantly higher in NPDR and PDR patients than in non-DR patients in subgroup analyses, and detection of peripheral serum IL-17A concentrations could help to assess the risk of progression from NPDR to PDR. Sensitivity analyses suggested that the results of the random-effects arithmetic were stable and reliable. Subgroup analyses based on assay method and sample source showed that the choice of these factors would largely influence the relationship between IL-17A levels and DR.
Elevated peripheral serum and ocular aqueous humor IL-17A levels in diabetic patients are associated with the risk of DR, IL-17A may serve as a potential predictor or therapeutic target for DR, and IL-17A may be an important predictor of inflammation for the progression of NPDR to PDR.
https://www.crd.york.ac.uk/prospero/, identifier CRD42024532900.
系统评价和 Meta 分析旨在确定眼房水和外周静脉血清样本中白细胞介素 17A(IL-17A)水平与糖尿病视网膜病变(DR)之间的关系。
从图书馆建设时间到 2023 年 9 月 20 日,检索 PubMed、Embase、Web of Science 和中国知网(CNKI)数据库。使用随机效应模型合并结果,进行敏感性分析以确定算法是否稳定可靠,并进行亚组分析以寻找可能的异质性来源。
共纳入 7 项病例对照研究。非增殖性糖尿病视网膜病变(NPDR)组的 IL-17A 水平高于非糖尿病视网膜病变(NDR)组[SMD=2.07,95%CI(0.45,3.68),P=0.01],增殖性糖尿病视网膜病变(PDR)组的 IL-17A 水平高于 NDR 组[SMD=4.66,95%CI(1.23,8.08),P<0.00001]。在亚组分析中,NPDR 和 PDR 患者的外周血清和房水 IL-17A 水平明显高于非 DR 患者,检测外周血清 IL-17A 浓度有助于评估从 NPDR 进展为 PDR 的风险。敏感性分析表明,随机效应算法的结果稳定可靠。基于检测方法和样本来源的亚组分析表明,这些因素的选择会在很大程度上影响 IL-17A 水平与 DR 之间的关系。
糖尿病患者外周血清和眼房水中白细胞介素 17A(IL-17A)水平升高与 DR 风险相关,IL-17A 可能作为 DR 的潜在预测因子或治疗靶点,IL-17A 可能是 NPDR 进展为 PDR 的炎症的重要预测因子。
https://www.crd.york.ac.uk/prospero/,标识符 CRD42024532900。